Anupam Rasayan IPO - Valuation And View: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Anupam Rasayan Ltd. is engaged in manufacturing of custom synthesis and specialty chemicals in India.
The company enjoys long standing relationship with its customers, given its fully integrated operations with presence across the value chain. It derives 87% of its revenue from top 10 customers with whom it has long term agreements between two to five years.
The company has significantly expanded its product portfolio to 41 of which Life science products catering to agrochemicals, personal care and pharma contribute ~90% of revenue while exports form 60%.
Development of new complex chemistries like hydrogenation, photo chlorination along with focus on higher value products would help in increasing the wallet share further.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.